129 related articles for article (PubMed ID: 11567914)
1. [Oxaliplatin tolerance in the treatment of metastatic colorectal cancers].
Bugat R
Bull Cancer; 2001 Aug; 88 Spec No():S45-9. PubMed ID: 11567914
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin in practice.
Misset JL
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-related side effects: characteristics and management.
Cassidy J; Misset JL
Semin Oncol; 2002 Oct; 29(5 Suppl 15):11-20. PubMed ID: 12422304
[TBL] [Abstract][Full Text] [Related]
4. Safety of oxaliplatin in the treatment of colorectal cancer.
Haller DG
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):15-20. PubMed ID: 11204657
[TBL] [Abstract][Full Text] [Related]
5. [Oxaliplatin: a first DACH-platinum in oncology].
Laadem A; Cvitkovic E
Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.
Wiseman LR; Adkins JC; Plosker GL; Goa KL
Drugs Aging; 1999 Jun; 14(6):459-75. PubMed ID: 10408744
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
10. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin-safety profile: neurotoxicity.
Grothey A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin-induced immune pancytopenia.
Taleghani BM; Meyer O; Fontana S; Ahrens N; Novak U; Borner MM; Salama A
Transfusion; 2005 May; 45(5):704-8. PubMed ID: 15847658
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin-related neurotoxicity: how and why?
Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
15. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
[TBL] [Abstract][Full Text] [Related]
16. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.
Garziera M; Virdone S; De Mattia E; Scarabel L; Cecchin E; Polesel J; D'Andrea M; Pella N; Buonadonna A; Favaretto A; Toffoli G
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653974
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
18. [Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer].
André T; Louvet C; Maindrault-Goebel F; Gramont AD
Bull Cancer; 2001 Aug; 88 Spec No():S20-5. PubMed ID: 11567910
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
[TBL] [Abstract][Full Text] [Related]
20. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
